Scientists assessing the non-clinical safety of potential drug candidates are often challenged by a lack of sufficient experimental data. Although relevant databases and reliable in silico tools exist for mutagenicity prediction, analogous resources for identifying potential organ toxicities are not as common or well developed. They therefore have to resort to suboptimal procedures such as literature searching and personal experience with similar compounds or classes.
Scientists assessing the non-clinical safety of potential drug candidates are often challenged by a lack of sufficient experimental data. Although relevant databases and reliable in silico tools exist for mutagenicity prediction, analogous resources for identifying potential organ toxicities are not as common or well developed. They therefore have to resort to suboptimal procedures such as literature searching and personal experience with similar compounds or classes.
However, there is a wealth of relevant data buried in the archives of the pharmaceutical industry that has not yet been leveraged. These data mainly exist in paper or PDF format and, consequently, are difficult to search and analyse. In order to overcome these limitations and advance early safety assessment, 13 pharmaceutical companies, 11 academic institutions and 6 small and medium-sized enterprises (SMEs) joined forces in the eTOX project (see Further information), which started in January 2010 under the sponsorship of the European Innovative Medicines Initiative (IMI). Since the availability of a wide and representative collection of historical data is fundamental for generating reliable predictions, the main goals of the eTOX project were: to build a shared and mineable database containing a broad and relevant collection of data (constituted mainly of repeat-dose toxicity studies contributed by the pharmaceutical companies participating in the project); and to use the database and other sources of information to enable more effective read-across and predictive modelling of safety end points.
The eTOX database and the eTOXsys platform At the end of the project in December 2016, the eTOX database (see Further information) contained 8,196 extracted toxicity studies carried out on 1,947 compounds, including nearly nine million preclinical data points (in-life observations, gross necropsies, histopathology and laboratory values such as clinical chemistry, haematology and urinalysis). The database contains repeat-dose studies conducted in various species (rat: 58%; dog: 28%; monkey: 7% and mouse: 5%), spanning different study durations (74% lasting up to 28 days, 17% between 29 and 91 days and 9% of longer duration (up to 2 years)) and diverse administration procedures (oral: 77%; intravenous: 14%). For a substantial fraction of the compounds, complementary information is included, such as pharmacokinetics (67%), pharmacological target (44%) and therapeutic indication (16%). The chemical structure is disclosed for most (75%) of the compounds present in the database.
Nearly 20% of the eTOX compounds are FDAapproved drugs and the chemical space covered by the eTOX database represents the internal chemical spaces of the pharmaceutical companies well, which is essential for obtaining reliable predictions and performing meaningful read-across. Another important feature for predictiveness is the presence of adequate numbers of positive and negative compounds.
The eTOX database and predictive models can be accessed using an integrated and user-friendly software platform: eTOXsys (see Further information). This platform incorporates a graphical user interface that enables sophisticated queries by providing an easy-to-use query builder to interrogate by various criteria such as substructure, structural similarity, study characteristics and finding type. The interface also enables the available models to be selected and run, and presents the predictions in a way that facilitates their visualization and interpretation by providing model metadata. eTOXsys enables the export of queries and predictions in commonly used formats. Moreover, the system incorporates an exploratory module that queries possible human safety liabilities for a compound on the basis of its similarity to marketed drugs based on profiles of both structure and toxicity.
Use and impact in industry eTOXsys is routinely used not only in early drug safety assessment in companies involved in eTOX, but also in later phases, such as the assessment of impurities in drug products that have not been qualified for in vivo studies. The main application is the comparison of hit or lead structures with compounds in the database to The sharing of legacy preclinical safety data among pharmaceutical companies and its integration with other information sources offers unprecedented opportunities to improve the early assessment of drug safety. Here, we discuss the experience of the eTOX project, which was established through the Innovative Medicines Initiative to explore this possibility.
raise hypotheses regarding organ toxicities (read-across). Importantly, the database can be searched for a particular pharmacological target to reveal whether other organizations have already pursued the same target. This is helping to assess whether toxicities in early in vivo studies are target related or associated with off-target interactions.
In certain circumstances, the data can be used to make head-to-head comparisons with competitor compounds without performing additional animal studies, thus contributing to 3R (Refine, Reduce and Replace) policies. Furthermore, the database can be used to analyse the correlation between the presence of chemical substructures and the occurrence of specific toxicities; for example, if a chemical moiety is suspected to be linked to hepatotoxicity, the substructure can be queried in the database in combination with liver findings. The result of this search can be compared with the background occurrence of the liver findings for all compounds. If a significantly higher incidence is found for the substructure, then there is high probability of causality, which can be managed by the medicinal chemists by modifying the substructure without discarding the whole molecule.
The eTOX database and other data resources, such as RepDose, ChEMBL and DrugBank, have been used by eTOX partners to develop nearly 200 predictive models, in which innovative modelling strategies have been applied 1, 2 . The extraction and integration of information from public sources for model development has been facilitated by a tool (Collector) that operates on top of the IMI Open PHACTS data infrastructure. In addition, the extraction of relevant information from free text (scientific literature or European public assessment reports) required the development and application of text mining techniques.
Independently of its use in drug development, the eTOX database is also contributing to the refinement of thresholds of toxicological concerns. A recent analysis of the no-observed-adverse-effect levels of systemic toxicity studies in eTOX supports the ICH Q3A defined concept that a lifetime dose to 1 mg per day of a nonmutagenic impurity would not represent a safety concern for patients 3 . This study also presented approaches to derive higher thresholds that could be acceptable for shorter administration periods during early clinical development.
Challenges, lessons and perspectives
The first challenge to be overcome by the eTOX consortium was the apprehension of pharmaceutical companies about sharing sensitive proprietary preclinical data. This required a combination of legal (consortium agreement), technical (database installed behind companies' firewalls and models implemented within self-contained virtual machines), organizational (the 'honest broker' concept), psychological (trust gained through collaboration), political (data-sharing pressure, such as the FAIR (Findability, Accessibility, Interoperability and Reusability) principles) and social (snowball effect) solutions.
The second challenge was the lack of standardization in the data contributed by the pharmaceutical companies. This required the collaborative development and implementation of relevant ontologies. The project developed a specific software tool (Ontobrowser) for facilitating such a cooperative task (see Supplementary information S1 (box)). We also carried out data curation campaigns to increase the quality of data incorporated into the database. Moreover, the raw data extracted from the reports was not directly appropriate for number crunching and had to be transformed into comparable toxicity scores suitable for modelling. Quick progress was obtained in hackathons organized by the eTOX consortium, which defined rules for summarizing related toxicological findings and identified underlying relationships between chemical structures and organ toxicities (such as causes of bilirubinaemia).
The development of a large number of models by diverse organizations, their integration into a single system (eTOXsys) and their adoption by the pharmaceutical industry was another challenge that required strict procedures and tools for enabling the harmonized development, documentation, validation and implementation of the models, as well as their versioning and maintenance. These tasks required the development of new tools including eTOXlab, a flexible modelling framework, ADAN 4 , a method for the assessment of the model applicability domain, and specific protocols for model validation 5 . Models were extensively documented following OECD QSAR reporting recommendations and stored in the eTOXsys Model Meta Database.
The eTOX IMI grant finished on December 2016 and the project entered into its sustainability phase with SME partners leading the commercial exploitation of eTOXsys. A user board with representatives of the different partners oversees the maintenance and exploitation processes. Finally, it should be stressed that recently funded IMI projects are extending the in silico toxicology domain furthered by the eTOX project. This is the case for the TransQST and eTRANSAFE projects, which show a clear focus on animal to human translation. TransQST is devoted to translational quantitative systems toxicology, while the eTRANSAFE project will push forward guidelines for legacy data sharing, and will jointly exploit preclinical data and clinical safety information for a better prediction of potential human safety liabilities.
